Definitive Contract HHSN261201300050C
Award Date
9/12/13
Potential Completion Date
9/30/14
Potential Value
$299K
Federal Agency
National Cancer Institute
Awardee
Glycan Therapeutics Corporation
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Chapel Hill, NC 27599, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Cancer Institute (NCI) to Glycoscientific, L.L.C., a small business research company. The contract is for the development of glycosylation-specific research reagents, including antibodies and aptamers, under SBIR Topic 294 Phase I. The contract has a ceiling value of $149,951 and was awarded on a firm fixed-price basis. This contract was set aside for total small business...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Glycohub, Inc., a woman-owned small business. The contract is for the delivery of chemically defined glycosphingolipid head groups, with a total ceiling value of $298,447.00 and a completion date of December 30, 2014. As an SBIR Phase I contract, this represents the initial research and development effort to explore the feasibility of the proposed technology....
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chemily LLC, a for-profit limited liability company. The contract has a ceiling value of $992,179.90 and is for the "CHEMO-ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED COMPLEX-TYPE N-GLYCANS." The work is to be performed in Atlanta, GA. This SBIR Phase II contract builds upon prior Phase I research and is focused on developing chemo-enzymatic...
This federal contract award, valued at $299,450.00, was issued by the National Cancer Institute, a civilian agency, to Glycobia, Inc., a for-profit limited liability company and manufacturer of goods. The contract is for a Small Business Innovation Research (SBIR) Program Phase I project titled "BOTTOM-UP GLYCOENGINEERING LIBRARY OF N-GLYCANS". The contract has a firm fixed price pricing type and was awarded on September 12, 2013 with a completion date of June 30, 2014. Glycobia,...
<p>The U.S. National Cancer Institute awarded a $1,300,000.00 Small Business Innovation Research (SBIR) Program Phase I contract to Cassia, LLC for the "ENZYMATIC SYNTHESIS OF GLYCANS." This is a Firm Fixed Price Definitive Contract with a period of performance through September 30, 2016. The contract is for research and development related to enzymatic synthesis of glycans, which are complex carbohydrate molecules.</p>
<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Omicron Biochemicals, Inc. The $999,991.00 fixed-price contract is for the "Synthesis of High-Mannose N-Glycans" and was awarded on September 18, 2015, with a completion date of September 17, 2017. The contract is a definitive contract, indicating it is a stand-alone award rather than under a larger contract vehicle.</p>
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Ancora Pharmaceuticals Inc. The $299,248.00 firm-fixed-price contract is for the synthesis of glycosaminoglycans. The contract was awarded on September 12, 2013 and has an ultimate completion date of March 31, 2015. Ancora Pharmaceuticals Inc. is a for-profit organization that is registered in the System for Award Management (SAM).</p>
This is a SBIR Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to Detroit R&D, Inc., a small business. The $147,520.00 fixed-price contract is for the development of glycosylation-specific research reagents, specifically antibodies and aptamers, under SBIR Topic 294. The contract was awarded on September 15, 2011 and has a completion date of December 14, 2012. Detroit R&D, Inc. is a minority-owned, for-profit,...